BioSig Technologies (BSGM -1.6%) has entered into a manufacturing and professional services agreement with Plexus (PLXS -0.0%).

Under the terms of the newly reached agreement, Plexus will bring to market the PURE EP System, the Company's signal processing technology for arrhythmia care, and develop a new product pipeline for BioSig's subsidiary NeuroClear Technologies.

The PURE EP is an FDA 510(k) cleared, a computerized platform for signal processing in patients undergoing electrophysiology (EP) procedures in an EP laboratory.

The Company recently completed its first multi-centered, prospective clinical trial and presented preliminary clinical data during the annual Heart Rhythm 2021 convention in July in Boston, MA.